Please login to the form below

Not currently logged in

ReveraGen BioPharma's

This page shows the latest ReveraGen BioPharma's news and features for those working in and with pharma, biotech and healthcare.

FDA receives Santhera and ReveraGens application for Duchenne muscular dystrophy treatment

FDA receives Santhera and ReveraGen’s application for Duchenne muscular dystrophy treatment

The US Food and Drug Administration (FDA) has received Santhera Pharmaceuticals (Santhera) and ReveraGen BioPharma’s completed rolling submission of a New Drug Application (NDA) for the priority review of vamorolone ... at an early age,” said Eric

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

The challenges of identifying rare diseases
With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...